HC Wainwright Has Lowered Expectations for Plus Therapeutics (NASDAQ:PSTV) Stock Price

Plus Therapeutics (NASDAQ:PSTV) had its target price decreased by equities research analysts at HC Wainwright from $3.00 to $2.00 in a research report issued to clients and investors on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price objective would suggest a potential upside of 268.32% from the stock’s current price.

PSTV has been the subject of a number of other reports. Maxim Group reduced their target price on shares of Plus Therapeutics from $4.00 to $3.00 and set a “buy” rating for the company in a report on Monday, August 18th. D Boral Capital upgraded Plus Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Wednesday, September 3rd. Zacks Research raised Plus Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Monday, October 13th. Wall Street Zen raised Plus Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Saturday, August 16th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Plus Therapeutics in a report on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $7.75.

Plus Therapeutics Trading Up 2.5%

PSTV opened at $0.54 on Monday. The business’s 50 day moving average is $0.56 and its 200-day moving average is $0.50. The stock has a market cap of $53.90 million, a PE ratio of -0.24 and a beta of 0.81. Plus Therapeutics has a twelve month low of $0.16 and a twelve month high of $2.31.

Plus Therapeutics (NASDAQ:PSTV) last posted its quarterly earnings data on Thursday, October 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.02). The firm had revenue of $1.40 million for the quarter, compared to analyst estimates of $1.50 million. As a group, analysts forecast that Plus Therapeutics will post -2.3 EPS for the current year.

Insider Buying and Selling at Plus Therapeutics

In other Plus Therapeutics news, Director Robert P. Lenk acquired 110,000 shares of the business’s stock in a transaction that occurred on Friday, August 22nd. The shares were purchased at an average price of $0.49 per share, with a total value of $53,900.00. Following the completion of the transaction, the director owned 139,327 shares in the company, valued at $68,270.23. The trade was a 375.08% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 0.79% of the stock is owned by company insiders.

Hedge Funds Weigh In On Plus Therapeutics

A hedge fund recently bought a new stake in Plus Therapeutics stock. Jane Street Group LLC purchased a new position in shares of Plus Therapeutics, Inc. (NASDAQ:PSTV) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 117,454 shares of the company’s stock, valued at approximately $41,000. Jane Street Group LLC owned about 0.19% of Plus Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 3.28% of the company’s stock.

About Plus Therapeutics

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.